Clinical characteristics and p16 status of study group
| Parameter . | Number (percentage) . |
|---|---|
| Total no. | 45 |
| Sex | |
| Female | 14 (31) |
| Male | 31 (69) |
| Age | |
| <1 y | 1 (2) |
| 1 y-10 y | 30 (67) |
| >10 y | 14 (31) |
| Immunophenotype | |
| T-ALL | 13 (29) |
| B-lineage ALL | 32 (71) |
| WCC at diagnosis | |
| <50 000 × 106/L | 26 (58) |
| ≥50 000 × 106/L | 19 (42) |
| P16genotype | |
| G/G | 28 (62) |
| D/D | 11 (25) |
| G/D | 6 (13) |
| Parameter . | Number (percentage) . |
|---|---|
| Total no. | 45 |
| Sex | |
| Female | 14 (31) |
| Male | 31 (69) |
| Age | |
| <1 y | 1 (2) |
| 1 y-10 y | 30 (67) |
| >10 y | 14 (31) |
| Immunophenotype | |
| T-ALL | 13 (29) |
| B-lineage ALL | 32 (71) |
| WCC at diagnosis | |
| <50 000 × 106/L | 26 (58) |
| ≥50 000 × 106/L | 19 (42) |
| P16genotype | |
| G/G | 28 (62) |
| D/D | 11 (25) |
| G/D | 6 (13) |
T-ALL indicates T-lineage acute lymphoblastic leukemia: WCC, white cell count; G/G, germline p16; D/D p16deletion; G/D, hemizygous p16.